COMMUNIQUÉS West-GlobeNewswire

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
29/01/2026
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
29/01/2026
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products
29/01/2026
CHEYENNE, Wyo., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX), a medical technology and hygiene solutions company, today announced the confirmation of strategic manufacturing partnerships with [...]
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
29/01/2026
Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography [...]
NetraMark Strengthens Board Of Directors
29/01/2026
TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
29/01/2026
Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage [...]
The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of Directors
29/01/2026
STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors. After going to medical school at [...]
Immutep Quarterly Activities Report Q2 FY26
29/01/2026
Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China In January 2026, Immutep [...]
Glass House Brands Announces Appointment of Alison Payne, Heineken USA Chief Marketing Officer, to its Board of Directors
29/01/2026
Ms. Payne brings decades of international marketing experience from Heineken, PepsiCo, Kellog and Diageo, where she specializes in branding regulated consumer products LONG BEACH, Calif. and TORONTO, Jan. 29, 2026 ( [...]
Terrapin Beer Co. Turns Up the Volume with a New Brand Identity Rooted in Music, Art and Craft Beer Culture
29/01/2026
A modern visual evolution designed to amplify artistic storytelling across the brand portfolio ATHENS, Ga., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Terrapin Beer Co. (Terrapin), a craft beer brand by Tilray Brands, Inc. ( [...]
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
29/01/2026
SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant [...]
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
29/01/2026
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients [...]
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
29/01/2026
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29/01/2026
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
29/01/2026
Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial (PRIOH-1, NCT03073967 ) [...]
Dogecoin Cash, Inc. Announces Completion of Unit Distribution Processing and DTC Participant Allocation
29/01/2026
MESQUITE, NV, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Mesquite, Nevada - January 29, 2026 - Dogecoin Cash, Inc. (OTC: DOGP) (the "Company") today announced that Colonial Stock Transfer Company, Inc. ("Colonial"), the Company' [...]
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
29/01/2026
BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). [...]
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29/01/2026
REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has [...]
Communiqué de presse : 2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026
29/01/2026
2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026. Paris, le 29 janvier 2026 Ventes du T4 en progression de 13,3 % à TCC 1 et BNPA 2 des activités de [...]

Pages